Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Survodutide Formulations
NCT06772532Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2025
- Primary completion
- May 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of survodutide in obesity and Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to last quantifiable point at 22 days and Maximum measured concentration at 22 days. Started Feb 2025; status: completed.
02
Drugs
03
Conditions
obesityNonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06772532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772532.